Neurovance Garners $1,500,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5feed7c6-744b-4fa1-9150-baf187d7b7e4 - Date
12/3/2016 - Company Name
Neurovance - Mailing Address
43 Thorndike Street Cambridge, MA 02141 USA - Company Description
Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD. - Website
http://www.neurovance.com - Transaction Type
Debt - Transaction Amount
$1,500,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. 7 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed
